Janssen R&D (Ireland) and Johnson & Johnson (China) Investment Ltd. have disclosed fused heterocyclic derivatives reported to be useful for the treatment of hepatitis B virus (HBV) infections.
Animal models recapitulating the immune features of chronic hepatitis B (CHB) are very limited. An Osaka University research team has developed a novel murine model of CHB and tested the efficacy and immunomodulating effects of interferon-α (IFN-α) therapy.
Researchers from Gilead Sciences Inc. presented preclinical data for the hepatitis B virus (HBV) vaccine candidates GS-2829 and GS-6779. Conservation analysis and functional immunogenicity screening were applied to identify optimized anti-hepatitis B surface antigen (HBsAg).
Researchers from Aligos Therapeutics Inc. have described the discovery of novel liver-targeted oral PD-L1 small-molecule inhibitors for the treatment of chronic hepatitis B and liver cancers.
Pegylated interferon-α (PegIFNα) is a treatment option for chronic hepatitis B (CHB) patients, but it often has undesirable side effects and not all patients respond to treatment. Tripartite motif-containing protein 26 (TRIM26) has been reported to have an impact on hepatitis C virus replication; researchers aimed to investigate the role of TRIM26 in CHB as well as its potential impact on response to PegIFNα in two cohorts of patients with CHB (N=945) treated for 48 weeks with a follow-up period of 24 weeks.
Researchers from Assembly Biosciences Inc. presented the discovery and preclinical characterization of novel small-molecule hepatitis B (HBV) and D virus (HDV) entry inhibitors.
F. Hoffmann-La Roche Ltd. has discovered benzothiazolyl bicyclo[1.1.1]pentane derivatives acting as hepatitis B virus (HBV) HBeAg and HBsAg secretion inhibitors, reported to be useful for the treatment of HBV infections.
